Wednesday, March 29, 2017

NOAC 'Reasonably' Cost-Effective in Afib (CME/CE)

(MedPage Today) -- Apixaban analysis shows about $54k per QALY vs warfarin
via NOAC 'Reasonably' Cost-Effective in Afib (CME/CE)
by
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)